Takeda/Lundbeck depression candidate Brintellix outshines Servier's agomelatine
This article was originally published in Scrip
Executive Summary
Lundbeck has released data from the European Phase III REVIVE trial of its novel multimodal investigational depression pill Brintellix (vortioxetine, formerly known as Lu AA21004, partnered with Takeda for the US/Japan) showing it meets the primary efficacy endpoint of statistically significant superiority to Servier's Valdoxan (agomelatine). Both drugs are positioned as new alternatives for patients who have failed to respond adequately to conventional SSRI/SNRI treatments.